Insulin resistance for glucose metabolism in skeletal muscle is a key feature in non-insulindependent diabetes mellitus (NIDDM). Which cellular effectors of glucose metabolism are involved is still unknown. We investigated whether transmembrane glucose transport in vivo is impaired in skeletal muscle in nonobese NIDDM patients. We performed euglycemic insulin clamp studies in combination with the forearm balance technique (brachial artery and deep forearm vein catheterization) in six nonobese NIDDM patients and five age-and weight-matched controls. Unlabeled D-mannitol (a nontransportable molecule) and radioactive 3-O-methyl-D-glucose (the reference molecular probe to assess glucose transport activity) were simultaneously injected into the brachial artery, and the washout curves were measured in the deep venous effluent blood. In vivo transmembrane transport of 3-O-methyl-D-glucose in forearm muscle was determined by computerized analysis of the washout curves. At similar steady-state plasma concentrations of insulin (approximately 500 pmol/liter) and glucose (approximately 5.15 mmol/liter), transmembrane inward transport of 3-O-methyl-D-glucose in skeletal muscle was markedly reduced in the NIDDM patients (6.5 x 10(-2) +/-0.56 x 10(-2).min-1) compared with controls (12.5 x 10(-2) +/-1.5 x 10(-2).min-1, P < 0.005). Mean glucose uptake was also reduced in the diabetics both at the whole body level (9.25 +/-1.84 vs. 28.3 +/-2.44 mumol/min per kg, P < 0.02) and in the forearm tissues (5.84 +/-1.51 vs. 37. 
Introduction
Patients with non-insulin-dependent diabetes mellitus (NIDDM)' are characterized by defects in pancreatic /3 cell function and insulin action on target tissues ( 1) .
Skeletal muscle has been shown to be the principal site of insulin resistance, defined as a reduced ability to metabolize glucose after insulin stimulation (2) (3) (4) . Before being phosphorylated, glucose must be transported across the cell membrane via a facilitated diffusion system, mediated by specific transporters.
Recently, it has been recognized that transmembrane glucose transport actually is mediated by a family ofglucose transporters (5) . Each isoform of glucose transporter has a characteristic tissue distribution and a physiologic regulation of its own. For instance, the insulin-sensitive glucose transporter (glut 4) is expressed only in the insulin-dependent organs (skeletal muscle, heart, adipose tissue) (6) (7) (8) (9) .
Insulin accelerates transmembrane glucose transport in the insulin-sensitive tissues, primarily by recruiting glucose transporters from an intracellular pool and causing their insertion into the plasma membrane, although some evidence in favor of an insulin-mediated increase in the affinity ofglucose transporters for glucose also exists (10) (11) (12) (13) (14) (15) . Therefore, transmembrane glucose transport is a primary candidate step for causing skeletal muscle insulin resistance in non-insulin-dependent diabetics.
In an earlier study, morbid obesity, irrespective ofdiabetes, was shown to be associated with a defect in insulin-mediated glucose transport in human muscle strips in vitro. Diabetes itself was not associated with the impairment in glucose transport (16) . A recent report by Andreasson et al. showed that glucose transport was defective at supraphysiological insulin concentrations in human muscle strips taken from elderly nonobese diabetic patients; however, the impairment in glucose transport in these patients was less than evident at physiological insulin concentrations ( 17 ) . In a number of recent reports (18) (19) (20) (21) (22) , transcription and translation ofthe gene for the insulin-sensitive glucose transporter were found, almost uniformly (20) , to be normal in muscle biopsies obtained from non-insulin-dependent diabetics, although glucose transport activity was not simultaneously assessed. To the best of our knowledge, there are no published papers in which the in vivo activity of glucose transport in skeletal muscle of patients with NIDDM has been evaluated.
Recently, we developed a dual tracer method to assess transmembrane glucose transport in vivo in human skeletal muscle (23) and constructed the in vivo dose-response curve of glucose transport to insulin (24) . In this study, we used the same approach to assess whether transmembrane glucose transport in human skeletal muscle is resistant to insulin in NIDDM.
Methods
Subjects. We studied six subjects with NIDDM and five healthy controls matched for age and weight. All of the diabetic subjects fulfilled the criteria for the diagnosis of diabetes as established by the National Diabetes Data Group (25). All patients but one, who was newly diagnosed, were treated with oral sulfonylurea agents. Their medication was discontinued at least 8 d before the study. All subjects were free from any major disease other than diabetes mellitus and were taking no other medications. None ofthe normal subjects had a family history of diabetes. All subjects consumed an isocaloric diet containing > 200 g of carbohydrate/d for at least 3 d before the study. Other relevant characteristics of the study subjects are summarized in Table I .
All investigations were carried out in the postabsorptive state after a 10-12-h overnight fast. The purpose, nature, and potential risks ofthe study were explained to all subjects, and informed, written consent was obtained before their participation. The protocol was reviewed and approved by the Human Investigation Committee at the University of Texas Health Science Center at San Antonio, TX.
Experimental design. All studies were begun at 8:30 a.m. On the evening before the study, all of the diabetic patients were admitted to the Clinical Research Center and received an overnight intravenous infusion of insulin (0.6-1.5 pmol/min per kg), which was adjusted every hour in order to slowly achieve and maintain normoglycemia. Therefore, diabetic and normal subjects were studied at comparable plasma glucose concentrations. On the morning ofthe study, catheters were introduced percutaneously into the brachial artery and retrogradely into an ipsilateral deep forearm vein draining forearm muscle. The tip ofthe deep forearm vein catheter was advanced for a distance of 2 in. from the puncture site, and could not be palpated in any of the subjects. Previous studies have documented that such catheter placement allows sampling ofthe muscle bed perfused by either the radial or ulnar artery (26) . Catheter patency was maintained by a slow infusion of normal saline. To exclude blood flow to the hand, a pediatric sphyg- AtM to 400 mM of plasma mannitol concentration.
Calculations. Whole body uptake of exogenous glucose was calculated over the final 60 min of the clamp according to the following formula: uptake = glucose infusion rate + pool correction, where the pool correction takes into account the change in the whole body glucose pool, as estimated from the change in plasma glucose concentration (27). This correction was always < 5% of the glucose infusion rate during the insulin clamp. Since tritiated glucose was not used to quantitate hepatic glucose production, whole body uptake of exogenous glucose represents a low boundary for whole body glucose metabolism. However, we have previously shown that hepatic glucose output is completely suppressed in controls and diabetics at this insulin concentration (30) . Therefore, during the insulin clamp, the uptake, as measured by the above formula, is a close estimate ofthe rate of whole body glucose metabolism.
Forearm glucose uptake was quantitated according to the Fick principle: uptake = [arteriovenous concentration gradient] X blood flow, where blood glucose concentration was estimated from plasma glucose concentration and the hematocrit (Hct) according to the following formula (31 ):
blood concentration = plasma concentration X (1 -0.3 Hct).
Forearm blood flow was measured by indocyanine green dye dilution in the deep vein according to the following formula: blood flow rate = dye infusion rate/(dye concentration)/( 1 -Hct).
It should be emphasized that, by the law of mass conservation, under steady-state conditions forearm glucose uptake equals the irreversible metabolism of glucose by the cells. In forearm tissues, this irreversible metabolism is equivalent to the rate ofglucose phosphorylation. Strictly speaking, steady-state conditions are verified when all glucose masses and fluxes in the forearm are time invariant (32) . In these experiments, we were able to document near constancy ofglucose fluxes and concentrations at the inlet (artery) and the outlet (deep vein) ofthe forearm in the basal state and during the final 60 min ofthe euglycemic clamp studies, and we assumed that this reflected an analogous state in the inaccessible regions inside the forearm, specifically the intracellular glucose mass and glucose phosphorylation rate. There- fore, in this study forearm glucose uptake is considered to be equal to the rate of glucose phosphorylation, and the two terms are used interchangeably.
Measurement ofglucose transport. Our method to measure transmembrane glucose transport in vivo is based on the principle that D> mannitol is freely diffusible into the extracellular space but does not permeate the cell, whereas 3-0-methyl-D-glucose is transported by the same specific carriers as D-glucose (33) but does not undergo any further metabolism. Therefore, the kinetic differences between the two tracers essentially reflect the activity ofthe glucose carriers in transporting 3-0-methyl-D-glucose into and out ofthe intracellular space. Since forearm blood flow is -1% ofcardiac output (3, 23, 28) , recirculation of any substance injected into the brachial artery is negligible. Under such circumstances the forearm can be assimilated to an isolated organ perfused by a nonrecirculating medium. This experimental setting fulfills the criteria for the application of the multiple tracer dilution technique, which has been in use for over three decades to study transendothelial and cellular transport in isolated perfused preparations of animal organs (34, 35) . Fig. 1 shows a typical dual tracer washout curve ofD-mannitol and 3-0-methyl-D-glucose in a control subject and in a diabetic patient after hyperinsulinemia. These washout curves are shown because, owing to an almost unique coincidence, the kinetics of D-mannitol is similar in these two individuals, and therefore, by simple visual inspection it is possible to appreciate a substantial difference in 3-0-methyl-D-glucose kinetics between the two subjects. Within this time interval, at each time point the concentration of 3-0-methyl-D-glucose in the deep vein is lower than D-mannitol. From a qualitative viewpoint, the difference between the two tracers is roughly proportional to the activity of transmembrane glucose transport. However, transmembrane traffic of 3-0-methyl-D-glucose is composed of two transmembrane unidirectional fluxes: glucose transport into and glucose transport out of the cell. At this simplistic level of analysis, these two unidirectional fluxes cannot be discriminated, nor can quantitative comparisons be made within and between individuals and/or groups.
A linear flow compartmental model has been used to measure fractional 3-0-methyl-D-glucose transport into and out ofthe cell from the two tracer dilution curves. The model itself, its numerical identification, and the mathematical and statistical criteria used to assess its validity have been described in detail in an earlier publication (23). We also reported that the model predicted the correct values for both L-glucose (the extracellular marker used in the experiments reported in that paper) and 3-0-methyl-D-glucose mean transit times, as well as for the size of the sampling compartment (forearm deep vein), thereby fulfilling three different physioanatomic criteria ofvalidity (23). Salient features ofthe model are its ability to describe blood flow heterogeneity in the vascular structure, diffusion in the interstitial fluid, and kinetics of (maximal rate of glucose transport; units: millimoles per minute) of glucose transport, as well as from the turnover number (number of substrate molecules transported per minute by a single transporter molecule when the transporter is the rate-limiting factor; units: minutes-') of the glucose transporters. It can be shown (36, 37) It is of interest to examine the mutual relationship of kn and k0u, in a symmetric transport system. Muscle glucose transport is believed to be such a system (33) . By applying a process ofderivation analogous to the one used for Eq. 1 and assuming that glucose transport in skeletal muscle is symmetric (33) , it can be shown that: (2) where ICV is the intracellular volume ofdistribution of 3-0-methyl-Dglucose and Slc is the glucose concentration inside the cell. Therefore, assuming that ICV does not change, k0ut can increase as a consequence of either an increase in V'm, or a decrease in K'm oftransport, or, since intracellular glucose concentration is not clamped, a decrease in the intracellular glucose concentration.
Eqs. I and 2 can be rewritten as follows: 
Eq. 5 defines the relationship between km and k0., in a symmetric transport system obeying Michaelis-Menten kinetics, and shows that, in such a system, km and k0., are not bound to be equal to each other, and that the ratio kn./k0u, can assume different values, depending on the 3-O-methyl-r-glucose volumes of distribution, on the Km of glucose transport for the natural substrate and on the intracellular/extracellular glucose concentrations. It follows from this analysis that disequality of k. and k0u, is the most likely situation. Thus, the disequality between k-m and k0., we have observed in previous papers (23, 24) and in this study (see Results) is compatible with the operation ofa symmetric transport system. On the other hand, our data neither prove nor disprove that the transport system carrying 3-O-methyl-D-glucose into and out of the cells in our experiments is symmetric. To accomplish this task, we should have been able to independently measure all the parameters contained in the right member of Eq. 5 in order to predict the knI/k0., ratio and compare it with the kn./k0., ratio found through the kinetic analysis of our washout curves. The model has been numerically identified in each individual from the dual tracer data set by using nonlinear least-squares estimation, as implemented in the CONSAM program (38, 39) . Measurement error was assumed to be additive, uncorrelated, of zero mean, and with an experimentally determined variance. Coefficients of variation of 3-0-methyl-D-glucose ranged from 2 to 12% (higher when the tracer concentration was lower), whereas the coefficients of variation of D-mannitol ranged between 1.5 and 2%. During saline control studies, we have observed that the coefficients of variation of k, and k0u, are 12.9 and 20.2%, respectively (24) . Model fit was very good in all cases. In Fig. 2 we present the normalized residuals (i.e., the difference between measured and model predicted values divided by the standard deviation ofthe measurement) for D-mannitol and 3-O-methyl-D-glucose in controls and diabetics. It can be seen that no systematic deviation from zero can be detected in the residuals, and this ensures that the model structure is adequate to describe the data (40) . The transport parameters, ki. and k0u1, were estimated with good precision. The average coefficients of variations for kn and k0., were 17±5% (range: 5-49%) and 25±8% (range: 6-70%), in the basal state, and 8±0.5% (range: 4-10%) and 11±1.3% (range: 6-18%) during the euglycemic insulin clamps, respectively. Differences within and between groups were tested by Student's t test for paired and unpaired data, respectively. Correlation coefficients were computed by standard formulas (41) .
Results
Plasma glucose, insulin, and FFA levels. Basal plasma glucose concentration was similar in NIDDM patients and controls (5.5 1±0.91 vs. 5.12±0.12 mmol/liter). Basal plasma insulin concentration was higher in NIDDM patients than in controls (174±24 vs. 40.8±6 pmol/liter, P < 0.01), reflectingthe intravenous insulin administration that was needed to maintain normoglycemia in the diabetic patients. Basal plasma FFA concentration was lower in NIDDM patients than in controls (473±42 vs. 706±97 gmol/liter, P < 0.05), presumably because of the higher insulin concentration.
During the insulin clamp, arterial glucose concentration was 5.1±0.55 and 5.22±0.33 mmol/liter in NIDDM patients and controls, respectively, whereas arterial insulin concentration was elevated to 531±102 and 472±22 pmol/liter in the two groups (P < 0.01 vs. baseline values for both), respectively. In all insulin clamp studies the plasma glucose concentration was maintained within 8% ofthe desired goal, with coefficients ofvariation < 5%. During hyperinsulinemia, arterial FFA concentration fell to a similar plateau in both NIDDM patients and controls (203±41 vs. 170±40 ,umol/liter, P < 0.01 vs. respective baseline values for both).
Whole body andforearm glucose uptake. During the insulin clamp, whole body uptake of exogenous glucose was lower in NIDDM than in control subjects (9.25±1.84 vs. 28.3±2. 44 ,umol/min per kg ofbody weight, P < 0.02), thus documenting the presence of insulin resistance in these patients.
In the basal state, forearm blood flow was similar in NIDDM patients and controls (42.0±6.5 vs. 38.8±3.2 ml/min per kg, respectively). Hyperinsulinemia did not significantly change forearm blood flow either in diabetics or controls (41.7±5.6 vs. 40.2±3.2 ml/min per kg, respectively).
Basal rates of forearm glucose uptake (phosphorylation) were not significantly different in NIDDM patients and controls (7.36±1.21 vs. 4 Figure 4 . Estimated contribution of skeletal muscle (stippled portion ofthe column) to total glucose uptake (entire column) in controls (left) and non-insulin-dependent diabetics (right) after physiologic hyperinsulinemia. The data are not normalized per body weight because the index of adiposity (BMI; see Table I ) and the body weight (data not shown) were similar in the two groups.
< 0.001 vs. baseline value), but remained unchanged in NIDDM patients (5.84±1. 51 ,mol/min per kg, P < 0.02 vs. controls) (Fig. 3) . Forearm glucose uptake was extrapolated to the whole body level under the assumptions that (a) -80% of the forearm blood flow goes to muscle (42) , and (b) muscle represents 60% of the forearm volume (43) and 40% of the body weight (44) in both diabetic and nondiabetic individuals. By this extrapolation, skeletal muscle accounted for -81% of the defect in insulin sensitivity documented in the NIDDM patients (Fig. 4) .
Transmembrane glucose transport. The basal rate constants for inward (kn) and outward (kout) transmembrane 3-0-methyl-D-glucose transport in skeletal muscle were similar in NIDDM patients and controls (5.75 X 10-2±1.35 X 10-2 vs. 5.93 x 10-2±0.96 x 10--min-' and 3.8 X 10-2±0.92 X 10-2 vs. 4.6 X 10-2±0.9 x 102.min-', respectively). During the insulin clamp, fractional inward transport of 3-0-methyl-D> glucose (ki) in muscle was significantly lower in diabetics than in controls (6.5 X 10-2±0.56 X 10-2 vs. 12.5 X 10-2±1.5 X 10-2.min'-, P < 0.005), whereas kout was comparable in the two groups (4.7 X 10-2±0.7 X 10-2 vs. 5.25 X 10-2±0.77 X 10-2 . min-') ( Fig. 5) . Using the pooled data from NIDDM patients and controls, a positive correlation was found to exist between whole body glucose uptake, which measures insulin sensitivity, and transmembrane fractional inward transport of 3-0-methyl-D-glucose (r = 0.941, P < 0.001) (Fig. 6 ).
Discussion
Insulin resistance in NIDDM has been thoroughly investigated in the past by using a wealth of in vivo and in vitro techniques aiming at identifying the specific cellular site(s) responsible for tissue unresponsiveness to insulin. The issue is of considerable importance because insulin resistance is thought to play a triple role in the natural history of NIDDM: (a) it precedes the emergence ofNIDDM in subjects at risk (45, 46) ; (b) it predicts the onset of the diabetic state in subjects with impaired glucose tolerance (47) (48) (49) ; and (c) it plays a role in inducing and/or sustaining hyperglycemia (1) .
As transmembrane transport is the first step in glucose han- dling by the cell and is regulated by insulin in insulin-sensitive tissues (skeletal muscle, adipose tissue), specific attention has been devoted in the past to its function and regulation. Adipocytes have been the typical in vitro model to assess insulin sensitivity of glucose transport (50-52) because muscle tissue does not lend itselfeasily to in vitro study. However, the majority of a glucose load is disposed of by skeletal muscle (2-4, 53-56) and therefore the extrapolation of in vitro data in adipocytes to the in vivo situation in skeletal muscle may not be valid. Thus, in recent reports, glut 4 (the insulin-sensitive glucose transporter) content has been found to be decreased in adipocytes obtained from NIDDM patients (57, 58) , but is usually normal in skeletal muscle (18) (19) (20) (21) (22) .
In this context, obesity may be an additional confounding factor. Glucose transport in muscle strips from obese subjects with and without diabetes was shown to be unresponsive to insulin ( 16) . In a group of nonobese diabetics, glucose transport in in vitro incubated muscle strips taken during elective abdominal surgery was found to be insulin resistant at supra- at the only physiological concentration tested (600 pM), the results were less easily interpretable because the insulin-induced stimulation above basal was of similar magnitude in the two groups, although the NIDDM patients displayed a -20% decrease in the absolute value, which did not reach the statistical significance (17) . In that study the NIDDM patients also were somewhat more obese than the controls, and obesity per se impairs glucose transport in in vitro incubated human muscle (16) . Therefore, to answer the question whether insulin resistance of NIDDM conveys a defect in muscle glucose transport activity, it is necessary to investigate nonobese NIDDM patients at physiologic insulin concentrations.
In this study, using the forearm balance technique, we have been able to closely monitor the metabolic events occurring in vivo in human skeletal muscle. We show that skeletal muscle plays a primary role in the insulin resistance in NIDDM at the whole body level. These data are in agreement with previous studies by our laboratory (2) and others (3, 4) . We also show that, at high physiological insulin concentrations, no apparent insulin resistance in the metabolism of circulating FFA is present, because plasma FFA concentration is reduced to the same levels in both diabetics and controls. These data should not be considered at variance with an earlier study from our laboratory (30), because in this study insulin was infused overnight to normalize fasting glucose, thereby creating sustained hyperinsulinemia, which could ameliorate the subsequent response of circulatingFFA to insulin.
The rate at which glucose is metabolized across a limb bed under steady-state conditions equals the rate of glucose phosphorylation by the cells (32) . Therefore, the pathophysiologic meaning of both our data on forearm glucose uptake and previously published limb balance data (2-4) is that, after hyperinsulinemia, glucose phosphorylation is impaired in skeletal muscle of NIDDM patients. Shulman and colleagues recently demonstrated that glycogen formation, as quantitated by13C-NMR in vivo spectroscopy, is a major fate of the glucose taken up by skeletal muscle and that glycogen synthesis is significantly depressed in NIDDM (59). Reduced glucose phosphorylation and glycogen synthesis in skeletal muscle are, therefore, documented defects in NIDDM.
Much attention has been devoted to glycogen synthase, and the activity of this enzyme has been found to be reduced in muscle biopsies obtained from patients with NIDDM (60) (61) (62) (63) . Much less information is presently available about muscle glucose transport and hexokinase activity in NIDDM patients at physiological insulin concentrations. Recently, Rothman et al. have measured in vivo glucose-6-phosphate concentration in skeletal muscle by 3"P-NMR during hyperglycemic-hyperinsulinemic clamps and have provided experimental evidence that either glucose transport or glucose phosphorylation activity is impaired in NIDDM patients (64) . Of particular concern is that, being located proximally to hexokinase and glycogen synthase, a defect in glucose transport could cause a reduction in both glucose phosphorylation and glycogen formation. Although the in vitro data would suggest that muscle glucose transport is likely to be impaired in NIDDM patients at physiologic insulin concentrations (16, 17, skeletal muscle of nonobese NIDDM patients. Furthermore, our dual tracer technique has the unique feature of being a direct in vivo measurement of glucose transport activity in human skeletal muscle (23, 24) .
In examining transmembrane transport, which is inherently a nonlinear process (33) , it is mandatory that the plasma glucose concentration be the same across different study groups and experimental maneuvers in order to allow meaningful comparisons. This was the rationale for bringing the elevated glucose levels down to control values in our NIDDM patients by means of a low-dose intravenous overnight insulin infusion. Under these baseline conditions, in the postabsorptive state, our NIDDM patients exhibited rates ofglucose phosphorylation and transmembrane transport that were similar to those found in control subjects. However, it should be noted that euglycemia was obtained and maintained in NIDDM patients at the expense of a fourfold higher (-170 pmol/liter) peripheral insulin concentration compared with controls. In a previous study, we have shown that peripheral insulin levels in the range of 150-200 pmol/liter are indeed effective in stimulating glucose transport above the baseline value in young healthy individuals (24) . We do not know whether such a phenomenon occurred in our NIDDM patients during the overnight insulin infusion. At any rate, normal transmembrane glucose transport in skeletal muscle is an accompanying feature of normalizing postabsorptive glucose homeostasis in NIDDM patients by administering insulin. Whether it plays any important pathophysiological role in restoring postabsorptive euglycemia in NIDDM remains an unsettled issue.
The most important finding ofthis study is that after physiologic hyperinsulinemia and concomitant with a reduced rate of glucose phosphorylation, fractional inward glucose transport was decreased by -48% in nonobese NIDDM patients. Previous reports, by showing that transmembrane glucose transport is impaired in in vitro preparation ofhuman fat cells taken from NIDDM patients (50) (51) (52) pointed to glucose transport as a major candidate step for causing insulin resistance in skeletal muscle. Nevertheless, this is the first demonstration in vivo ofa specific defect in glucose transport in human skeletal muscle of nonobese, non-insulin-dependent diabetic patients. Furthermore, as a confirmation and an extension of our previous results (23, 24) , there was a good correlation between whole body glucose disposal rate and transmembrane glucose transport in human skeletal muscle during physiologic hyperinsulinemia (Fig. 6 ). Stated otherwise, the more insulin resistant an individual is, the less active glucose transport is in skeletal muscle.
In this study, we report that in NIDDM patients during euglycemic hyperinsulinemia, forearm glucose uptake and transmembrane inward glucose transport activity are, respectively, 16 and 52% ofthe values measured in the controls. Furthermore, in the passage from the basal to the hyperinsulinemic state, our control subjects exhibited a sevenfold increase in forearm glucose uptake, but only doubled fractional glucose transport. These findings are at odds with the widespread belief that a one-to-one relationship should hold between cellular transmembrane glucose transport and forearm glucose uptake. However 44 ,gmol/min per kg and -7.4 mM (54). As forearm glucose uptake is the low boundary for glucose transport, their findings imply that at a 5-mM glucose concentration transmembrane inward glucose transport should be no less than 18 gmol/min per kg. A twofold increase of this minimal estimate of glucose transport would be sufficient to sustain the rate of forearm glucose uptake observed by us in the control group. Moreover, as, according to our data, the fold increase in glucose transport (approximately twofold) is less than in forearm glucose uptake (approximately sevenfold), it is predicted that intracellular glucose concentration should fall in skeletal muscle of normal individuals after hyperinsulinemia. SchalinJantti et al. have recently reported that intracellular glucose concentration is indeed decreased in skeletal muscle biopsies taken from healthy individuals during a euglycemic insulin clamp at physiologic insulin concentrations (65) . Thus, our results are compatible with the available evidence on the role of glucose transport activity in determining muscle glucose metabolism in vivo in healthy humans and document that in vivo glucose transport is impaired in skeletal muscle of nonobese NIDDM patients.
The latter finding has some important implications. First, it shows that in the biochemical cascade that leads to reduced glucose phosphorylation and glycogen formation in NIDDM patients, transmembrane glucose transport is the first and most proximal effector to be impaired, and as such is a major determinant of peripheral insulin resistance in NIDDM. This does not rule out the existence of one or more additional defects located at more distal steps in intracellular glucose metabolism, such as, for instance, glycogen synthase (60) (61) (62) (63) .
Second, there is experimental evidence that in adipocytes of NIDDM patients, where glucose transport is known to be decreased (50) (51) (52) , glut 4 levels are reduced (57, 58) . Thus, in human adipocytes there is a parallel behavior between glut 4 content and glucose transport activity. Most recent data have shown that glut 4 levels in skeletal muscle of nonobese NIDDM subjects are normal (18) (19) (20) (21) (22) . Therefore, if the concomitant changes in glut 4 levels and transmembrane glucose transport documented in human adipocytes in vitro were a paradigm for the pathophysiology of glucose transport in human skeletal muscle in vivo, glucose transport in the latter tissue should be normal in NIDDM patients and should not be a component of insulin resistance in vivo. We show, instead, that glucose transport is insulin resistant in vivo in skeletal muscle of nonobese, non-insulin-dependent diabetics. As this insulin insensitivity is not caused by a decreased concentration of glut 4 (18) (19) (20) (21) (22) , it must be due to a defect in the intrinsic activity and/or the translocation to the plasma membrane of the glucose transporters (10) (11) (12) (13) (14) (15) Experimental evidence in favor of the former hypothesis has been provided both in vivo in the intact rat (66) and in in vitro preparations (67) (68) (69) (70) in which high glucose levels have been shown to desensitize transmembrane glucose transport to the stimulatory action of insulin. In addition, in human type 1 diabetes mellitus, hyperglycemia has been shown to be a cause of insulin resistance (71 ) . A corollary ofthe former hypothesis is that the defect in glucose transport should be ameliorated by strict glycemic control. Transmembrane glucose transport was, indeed, improved in adipocytes taken from NIDDM patients after treatment with insulin to improve glycemic control (72) .
To our knowledge, no data are available to substantiate or reject this hypothesis in human muscle.
As for the latter hypothesis, the only data in its support are from the study of relatives of NIDDM patients, who, at a time ofpreserved glucose homeostasis, display insulin resistance ofa degree not very different from that seen in overt diabetics (45, 46) . However, it is unknown whether in those individuals transmembrane glucose transport in skeletal muscle is impaired.
In summary, we have shown that transmembrane glucose transport is insulin resistant in the skeletal muscle of NIDDM patients and that this impairment is approximately proportional to their degree of insulin resistance. Since the content of the insulin-sensitive glucose transporter (glut 4) in muscle is not affected by NIDDM (18) (19) (20) (21) (22) , a defect in translocation and/or intrinsic activity of glut 4 may be present in nonobese NIDDM patients. Whether this defect precedes or follows the onset of hyperglycemia remains to be determined.
